Antineoplastic activity of didemnin congeners: nordidemnin and modified chain analogues. 1991

P Jouin, and J Poncet, and M N Dufour, and A Aumelas, and A Pantaloni, and S Cros, and G François
CCIPE, Montpellier, France.

Nordidemnin (2), a natural analogue of the marine cyclodepsipeptide didemnin B (1b), showed cytotoxic activity against L1210 leukemia and antineoplastic activity against P388 leukemia as well as B16 melanoma; nordidemnin (2) was as active as didemnin B (1b). The influence of synthetic modifications in the linear peptidic chain on in vitro and in vivo activity was also studied. Replacement of the terminal lactyl residue by mandelyl and 3-(p-hydroxyphenyl)propionyl residues in compounds 3 and 4, respectively, did not affect the cytotoxic activity against L1210 leukemia (ID50 of 1.1 nM and 1.2 nM, respectively) or the in vivo activity against P388 leukemia. Unlike these aromatic substituants, the lipophilic palmityl residue induced a dramatic loss in cytotoxic activity. The inverted chirality of the MeLeu joining residue in compound 6 caused a marked reduction in the in vitro activity.

UI MeSH Term Description Entries
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D007941 Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene. P388D(1) Leukemia,P388, Leukemia
D008546 Melanoma, Experimental Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA. B16 Melanoma,Melanoma, B16,Melanoma, Cloudman S91,Melanoma, Harding-Passey,Experimental Melanoma,Experimental Melanomas,Harding Passey Melanoma,Melanomas, Experimental,B16 Melanomas,Cloudman S91 Melanoma,Harding-Passey Melanoma,Melanoma, Harding Passey,Melanomas, B16,S91 Melanoma, Cloudman
D010456 Peptides, Cyclic Peptides whose amino acid residues are linked together forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS; some are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL). Circular Peptide,Cyclic Peptide,Cyclic Peptides,Cyclopeptide,Orbitide,Circular Peptides,Cyclopeptides,Orbitides,Peptide, Circular,Peptide, Cyclic,Peptides, Circular
D002621 Chemistry A basic science concerned with the composition, structure, and properties of matter; and the reactions that occur between substances and the associated energy exchange.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D047630 Depsipeptides Compounds consisting of chains of AMINO ACIDS alternating with CARBOXYLIC ACIDS via ester and amide linkages. They are commonly cyclized. Cyclic Depsipeptide,Cyclodepsipeptide,Depsipeptide,Peptolide,Peptolides,Cryptophycins,Cyclodepsipeptides,Depsipeptides, Cyclic,Cyclic Depsipeptides,Depsipeptide, Cyclic
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

P Jouin, and J Poncet, and M N Dufour, and A Aumelas, and A Pantaloni, and S Cros, and G François
December 1998, Bioorganic & medicinal chemistry letters,
P Jouin, and J Poncet, and M N Dufour, and A Aumelas, and A Pantaloni, and S Cros, and G François
January 2001, European journal of medicinal chemistry,
P Jouin, and J Poncet, and M N Dufour, and A Aumelas, and A Pantaloni, and S Cros, and G François
July 2001, Bioorganic & medicinal chemistry letters,
P Jouin, and J Poncet, and M N Dufour, and A Aumelas, and A Pantaloni, and S Cros, and G François
May 2000, Current pharmaceutical design,
P Jouin, and J Poncet, and M N Dufour, and A Aumelas, and A Pantaloni, and S Cros, and G François
January 1991, Journal of medicinal chemistry,
P Jouin, and J Poncet, and M N Dufour, and A Aumelas, and A Pantaloni, and S Cros, and G François
October 2003, Molecular cancer therapeutics,
P Jouin, and J Poncet, and M N Dufour, and A Aumelas, and A Pantaloni, and S Cros, and G François
February 2006, Bioorganic & medicinal chemistry letters,
P Jouin, and J Poncet, and M N Dufour, and A Aumelas, and A Pantaloni, and S Cros, and G François
October 1981, Journal of medicinal chemistry,
P Jouin, and J Poncet, and M N Dufour, and A Aumelas, and A Pantaloni, and S Cros, and G François
February 1993, Archiv der Pharmazie,
P Jouin, and J Poncet, and M N Dufour, and A Aumelas, and A Pantaloni, and S Cros, and G François
June 2011, Organic & biomolecular chemistry,
Copied contents to your clipboard!